Quick Facts

• Therapeutic Area: Dermatology
• Main Use: Management of androgenetic alopecia (pattern hair loss)
• Action: Helps to reduce hair thinning and stimulate hair growth

---

Avicis is a medicine used to address androgenetic alopecia, which is commonly known as pattern hair loss or male-pattern baldness and female-pattern hair loss. The topical solution is applied to the scalp and is intended to slow the progression of hair loss.

The clinical effect is related to its active ingredient, alfatradiol (17alpha-estradiol), which is a weak estrogen. It is understood to act by weakly inhibiting the enzyme 5alpha-reductase. This enzyme is responsible for converting the hormone testosterone into dihydrotestosterone (DHT), a substance that plays a key role in the process of hair follicle miniaturization in individuals with this type of hair loss.

By helping to decrease the production of DHT at the hair follicle level, Avicis works to reduce hair thinning and can help to stimulate hair growth and maintain existing hair density in the affected areas of the scalp. Avicis is a nationally authorized medicine in specific European Union member states. Treatment is intended for continuous application to maximize the benefits.

Avicis is officially restricted to specific patient populations defined by regulatory authorities. The medicine is primarily intended for use by adults (18 years and older) diagnosed with androgenetic alopecia.

Absolute Contraindication

The product is contraindicated and must not be used by individuals with a known hypersensitivity or allergy to the active ingredient, Alfatradiol, or to any of the non-active components (excipients) in the topical solution.

Populations Where Use is Not Recommended

Regulatory documents establish that use is not recommended in several key groups due to insufficient safety and efficacy data.

• Pediatric Use: Children and adolescents under 18 years of age are advised against using the product.
• Pregnancy and Lactation: Use is not recommended during pregnancy or lactation (breastfeeding), as the effects on fetal and infant development have not been sufficiently studied by regulatory bodies.

Conditional Restrictions

Avicis is meant for application on a sound scalp. Individuals with scalp infections, open wounds, or other pre-existing dermatological conditions at the application site should seek professional consultation before use. No specific restrictions concerning hepatic impairment or renal impairment are documented in the publicly available regulatory summaries for this medicine.

Interactions with other medicines and products

The official regulatory profile for Avicis (Alfatradiol) is defined by its method of administration and subsequent systemic exposure. Because this medicine is a topical solution applied directly to the scalp, its absorption into the bloodstream is minimal. This characteristic is the official basis for its interaction profile, as documented in authoritative regulatory sources.

---

Interaction Scope and Status

The regulatory label for Avicis and similar Alfatradiol topical solutions confirms the following official interaction status, due to the minimal systemic availability:

Category	Official Regulatory Status
Specific interacting medicines	None documented.
Metabolic/Transporter Interactions	None documented.
Timing-based interaction rules	None documented.
Interaction-related restrictions	None documented.

---

Resulting Interaction Structure

The prescribing information issued by national medicines authorities states explicitly that no interactions with other medicines or products are currently known. Formal drug-drug interaction studies were not deemed necessary or conducted due to the negligible systemic availability. Consequently, the product label does not specify any contraindicated combinations, no substances are listed as altering the drug’s plasma levels, and there are no requirements for separating the administration of Avicis from other oral or systemic medications. This official status reflects the low risk of clinically significant systemic effects.

The action of Alfatradiol is centered on modulating a specific hormonal pathway at the enzyme level, ensuring its primary physiological effect remains localized to the scalp.

---

Local Inhibition of 5alpha-Reductase

The primary mechanism involves Alfatradiol acting as a competitive inhibitor against the enzyme 5alpha-Reductase within hair follicle cells. This interaction suppresses the enzyme’s ability to convert Testosterone into the more potent androgen, Dihydrotestosterone (DHT). By intervening at this early, molecular step, the drug limits the production of the key mediator active in follicular pathology.

---

Suppression of Follicular Androgen Signaling

The resulting reduction in local DHT concentration directly lessens the impact on the Androgen Receptors (ARs) in the hair follicle's dermal papilla. This suppression of receptor activation interrupts the specific signaling cascade that contributes to progressive follicular shrinking and miniaturization. This adjustment of the hormonal pathway alters the physiological process within the hair follicle.

---

Stereoisomer Selectivity and Targeted Action

Alfatradiol's chemical structure as the 17alpha-Estradiol stereoisomer is critical for its targeted mechanism. This unique configuration exhibits selectivity for 5alpha-Reductase while simultaneously conferring minimal affinity for systemic Estrogen Receptors, ensuring the mechanism remains peripheral and focused on local enzyme modulation.

How to Use Avicis: Administration Guidelines

Avicis (Alfatradiol 0.025% solution) is administered via the topical route, meaning the solution is applied directly to the scalp. Its use is defined by a structured, long-term protocol intended for adults.

Application Route and Frequency

The standard strength is a 0.025% ethanolic topical solution. This formulation is applied directly to the affected areas of the scalp and must not be rinsed off after application.

Treatment Phase	Dosing Schedule	Application Condition
Initial Treatment	Once daily application of 1 mL (in some labels, up to twice daily)	Applied to a clean, dry scalp using the specialized applicator
Maintenance Phase	Frequency may be reduced to every second or third day	Continuous application required to maintain results

Procedural Instructions and Course Duration

The medicine is dispensed via a specialized applicator designed to ensure the proper volume and even distribution across the scalp. Guidance indicates that using volumes greater than the recommended dose, or increasing the frequency beyond the schedule, will not enhance clinical stabilization.

Treatment with Avicis is designed as a continuous, long-term commitment. Initial visible results typically require at least two to four months of consistent daily use before changes are observed. Discontinuation of the continuous regimen may lead to a relapse of the hair condition. If an application is missed, users are instructed to continue with the next scheduled application and avoid compensating with an extra dose.

Research Evidence / Overview of Studies

Primary Raynaud’s Phenomenon (RP)

Multiple placebo-controlled, double-blind randomized clinical trials (RCTs) investigated the change in symptoms of primary Raynaud’s phenomenon.

• Research into Drug Characteristics
  • Early research focused on properties that may affect blood vessel dilation. The study explored whether the drug affected blood flow to the fingers and toes, and examined potential measurements in the frequency of attacks.
• Outcomes and Evaluation Data
  • Larger, long-term studies have been conducted. These studies evaluated outcomes related to the severity and duration of vasospastic attacks.
  • Safety and tolerability were a focus of the evaluation. This research also tracked the frequency of events reported by participants.

---

Secondary Raynaud’s Phenomenon

Research into its use for secondary Raynaud’s is more limited. The existing evidence primarily comes from smaller, open-label observational studies.

• Combination Therapy Research
  • Limited investigation has been conducted on its use alongside other established vasodilators. A small trial investigated whether combining the drug with standard calcium channel blockers affected the duration of attack-free periods.

---

Dosage and Administration

Clinical research has focused on identifying a minimal dose that was used in research.

• Dose-Response Findings
  • One key study reported findings on whether a lower dose produced comparable measurements with fewer reported side effects. This research examined the relationship between dosage and the occurrence of adverse events.

---

Other Research Applications

The characteristics observed in the drug's action have led to additional research. Its use is also a subject of research concerning other peripheral vascular diseases. Studies in this area are still preliminary.

Common questions about Avicis (FAQ)

---

Q: How quickly should I expect Avicis to start working?

A: Official guidance indicates that initial visible changes may require at least two to four months of consistent daily application before they are observed. Because Avicis is used to support stabilization, the treatment is intended to be a continuous protocol to support the stabilization of the condition.

---

Q: Are there any common foods or drinks I should avoid while using Avicis?

A: The official regulatory profile states that no interactions with other medicines, food, or drinks are currently known. This status is based on the characteristics of the topical solution, which has minimal absorption into the bloodstream.

---

Q: Can women use Avicis?

A: Avicis is prescribed for pattern hair loss, a condition that affects both men and women. According to the official safety constraints, its use is officially not recommended or should be avoided only during pregnancy and breastfeeding.

---

Q: What is the difference between Avicis and similar medicines I see advertised?

A: Avicis is described in official documents as a selective 5alpha-Reductase inhibitor that is applied as a topical solution directly to the scalp. Its low systemic absorption is a characteristic that helps to define its profile in relation to medicines that are taken orally (by mouth) and may have systemic effects.

---

Q: Can Avicis be taken with or without food?

A: Since Avicis is a topical solution that is applied directly to the scalp and is not swallowed, its application is independent of food or meal timing. Because it is applied topically to the scalp, considerations regarding taking it with or without food do not apply.

---

Q: What is the difference between the ingredient in Avicis and a related compound?

A: The active ingredient, Alfatradiol, is chemically known as 17alpha-Estradiol, which is a specific version (a stereoisomer) of a natural hormone. This specific chemical structure is noted for enabling the ingredient to modulate the relevant enzyme locally, while exhibiting minimal systemic hormonal activity.

---

Q: Do all people experience side effects from Avicis?

A: Official drug documents list adverse reactions by how often they occur, indicating that many people may not experience side effects. The most commonly reported effects are localized skin reactions at the application site, such as irritation or redness.

---

Q: Is Avicis addictive or habit-forming?

A: Avicis is a selective 5alpha-Reductase inhibitor. It is not classified as a controlled substance in authoritative drug schedules and is not reported as having addictive or habit-forming properties in regulatory documents.

---

Q: Will Avicis definitely work for my condition?

A: The product's purpose is described in official documents as supporting the stabilization of the condition. While clinical research has examined outcomes related to the severity of the condition, official sources do not contain claims or assurances about specific individual results.

---

Q: Is Avicis considered safe for long-term use?

A: The official administration protocol for Avicis defines treatment as a continuous, long-term commitment. The official product documentation defines its use as being part of this specific continuous, long-term regimen.

---

Q: What should I do if I suspect an interaction between Avicis and another medicine?

A: If you believe you are experiencing a medical concern or a suspected interaction, official medical guidance emphasizes the importance of informing a healthcare professional, such as a doctor or pharmacist, about the observation.

---

Q: Why does Avicis have a warning about certain medical conditions?

A: The medicine is contraindicated for individuals with a known hypersensitivity to the ingredients, meaning an allergic reaction is possible. Use is also officially restricted on the scalp if there are open wounds or infections. These restrictions are in place to address the potential for increased local absorption or adverse tissue effects.

---

Q: What if I am taking multiple medications, is Avicis still appropriate?

A: The official regulatory label states that no interactions with other medicines are currently known. This status is primarily based on the negligible absorption into the bloodstream that results from the drug’s topical application.

---

Q: Can Avicis cause changes to the skin or hair?

A: Commonly reported adverse reactions are localized skin changes at the application site, which can include irritation, itching, redness, or a burning sensation. Official regulatory documents do not specifically list general changes to hair texture or color as expected effects.

Official Storage and Disposal Requirements

Storage and disposal instructions for Avicis (Alfatradiol topical solution) are defined by regulatory labeling to maintain product stability and ensure environmental safety.

Storage Conditions

Requirement	Rule
Temperature	No special storage temperature conditions are required.
Protection	Keep the product in the original container and ensure it is correctly closed after each use.
Child Safety	Store the medicine out of the sight and reach of children.
Stability	Do not use the solution after the printed expiration date.

Disposal Instructions

Official regulations prohibit disposing of unused or expired Avicis solution in household waste, sinks, or wastewater systems. The product must be discarded according to local pharmaceutical waste regulations to prevent environmental contamination.